Browse the corpus

REFERENCES Arsura EL, Ismail Y, Freedman S, et al, “Amphotericin B-Induced Dilated Cardiomyopathy,” Am J Med , 1994, 97(6):560-2. [PubMed 7985716 ] Benson JM and Nahata MC, “Clinical Use of Systemic Antifungal Agents,” Clin Pharm , 1988, 7(6):424-38. [PubMed 3042267 ] Benson JM and Nahata MC, “Pharmacokinetics of Amphotericin B in Children,” Antimicrob Agents Chemother , 1989, 33(11):1989-93. [PubMed 2610508 ] Branch RA, “Prevention of Amphotericin B-Induced Renal Impairment. A Review on the Use of Sodium Supplementation,” Arch Intern Med , 1988, 148(11):2389-94. [PubMed 3056312 ] Centers for Disease Control and Prevention, “Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,” MMWR Recomm Rep , 2009, 58(RR-11):1-166. Available at file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf [PubMed 19730409 ] Cruz JM, Peacock JE Jr, Loomer L, et al, “Rapid Intravenous Infusion of Amphotericin B: A Pilot Study,” Am J Med , 1992, 93:123-30. [PubMed 1497007 ] Devuyst O, Goffin E, and Van Ypersele de Strihou C, “Recurrent Hemiparesis Under Amphotericin B for Candida albicans Peritonitis,” Nephrol Dial Transplant , 1995, 10(5):699-701. [PubMed 7566587 ] Gales MA and Gales BJ, “Rapid Infusion of Amphotericin B in Dextrose,” Ann Pharmacother , 1995, 29(5):523-9. [PubMed 7655137 ] Gallis HA, Drew RH, and Pickard WW, “Amphotericin B: 30 Years of Clinical Experience,” Rev Infect Dis , 1990, 12(2):308-29. [PubMed 2184499 ] Goodwin SD, Cleary JD, Walawander CA, et al, “Pretreatment Regimens for Adverse Events Related to Infusion of Amphotericin B,” Clin Infect Dis , 1995, 20(4):755-61. [PubMed 7795069 ] Gould FK, Denning DW, Elliott TS, et al, “Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,” J Antimicrob Chemother , 2012, 67(2):269-89. [PubMed 22086858 ] Jeffery GM, Beard ME, Ikram RB, et al, “Intranasal Amphotericin B Reduces the Frequency of Invasive Aspergillosis in Neutropenic Patients,” Am J Med , 1991, 90(6):685-92. [PubMed 2042684 ]

Gould FK, Denning DW, Elliott TS, et al, “Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,” J Antimicrob Chemother , 2012, 67(2):269-89. [PubMed 22086858 ] Jeffery GM, Beard ME, Ikram RB, et al, “Intranasal Amphotericin B Reduces the Frequency of Invasive Aspergillosis in Neutropenic Patients,” Am J Med , 1991, 90(6):685-92. [PubMed 2042684 ] Jones RS, Barman A, Suh B, et al, “Successful Treatment of Aspergillus vertebral Osteomyelitis With Amphotericin B Lipid Complex,” Infect Dis Clin Pract , 1995, 4:237-9. King CT, Rogers PD, Cleary JD, et al, "Antifungal Therapy During Pregnancy," Clin Infect Dis , 1998, 27(5):1151-60. [PubMed 9827262 ] Kintzel PE and Smith GH, “Practical Guidelines for Preparing and Administering Amphotericin B,” Am J Hosp Pharm , 1992, 49(5):1156-64. [PubMed 1595747 ] Koren G, Lau A, Klein J, et al, “Pharmacokinetics and Adverse Effects of Amphotericin B in Infants and Children,” J Pediatr , 1988, 113(3):559-63. [PubMed 3411404 ] Lyman CA and Walsh TJ, “Systemically Administered Antifungal Agents. A Review of Their Clinical Pharmacology and Therapeutic Applications,” Drugs , 1992, 44(1):9-35. [PubMed 1379913 ] Mactal-Haaf C, Hoffman M, and Kuchta A, "Use of Anti-infective Agents During Lactation, Part 3: Antivirals, Antifungals, and Urinary Antiseptics," J Hum Lact , 2001, 17(2):160-6. [PubMed 11847833 ] Mohr J, Johnson M, Cooper T, et al, “Current Options in Antifungal Pharmacotherapy,” Pharmacotherapy , 2008, 28(5):614-45. [PubMed 18447660 ] Pappas PG, Kauffman CA, Andes D, et al, “Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,” Clin Infect Dis , 2009, 48(5):503-35. [PubMed 19191635 ] Patel R, “Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine,” Mayo Clin Proc , 1998, 73(12):1205-25. [PubMed 9868423 ] Perfect JR, Dismukes WE, Dromer F, et al, “Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,” Clin Infect Dis , 2010, 50(3):291-322. [PubMed 20047480 ]

Patel R, “Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine,” Mayo Clin Proc , 1998, 73(12):1205-25. [PubMed 9868423 ] Perfect JR, Dismukes WE, Dromer F, et al, “Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,” Clin Infect Dis , 2010, 50(3):291-322. [PubMed 20047480 ] Rex JH, Bennett JE, Sugar AM, “A Randomized Trial Comparing Fluconazole With Amphotericin B for the Treatment of Candidemia in Patients Without Neutropenia. Candidemia Study Group and the National Institute,” N Engl J Med , 1994, 331(20):1325-30. [PubMed 7935701 ] Rex JH, Walsh TJ, Sobel JD, et al, “Practice Guidelines for the Treatment of Candidiasis. Infectious Diseases Society of America," Clin Infect Dis , 2000, 30(4):662-78. [PubMed 10770728 ] Slain D, “Lipid-Based Amphotericin B for the Treatment of Fungal Infections,” Pharmacotherapy , 1999, 19(3):306-23. [PubMed 10221369 ] Stevens DA and Shatsky SA, "Intrathecal Amphotericin in the Management of Coccidioidal Meningitis," Semin Respir Infect , 2001, 16(4):263-9. [PubMed 11740828 ] The Ad Hoc Advisory Panel on Peritonitis Management. “Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis Treatment Recommendations: 1989 Update,” Perit Dial Int , 1989, 9(4):247-56. [PubMed 2488376 ] Topic 8701 Version 39.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]